Result
MRMP was identified in 43% of the patients tested within March 2013 to August 2013. No single clinical characteristic or laboratory markers were reliable in differentiating between MSMP and MRMP. A clinical parameter of non-defervescence at 72 hours was identified as a good clinical indicator for likely macrolide resistance. 96% of MSMP patients achieved defervescence by 72 hours. There were 5 patients that developed pleural effusion and 80% of them belonged to the MRMP group. All of the 15 patients treated with doxycycline, were able to achieve rapid defervescence within 24 hours. The overall length of stay was longer in the MRMP group.